-

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and related industries. In its first year of eligibility for the award, Ionis was ranked second based on industry-leading innovation, strong alignment of company and employee values, employee loyalty and a culture of respect.

“Our people are our greatest strength at Ionis. We’re thrilled to be featured as the #2 top employer by Science in our first year considered for the list – an accomplishment that reflects both the caliber of our science and the unique spirit of the Ionis culture,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Our team is driven, inquisitive and passionate, and their hard work empowers Ionis to make the breakthroughs that transform the lives of people living with serious diseases.”

The Science and Science Careers’ 2025 Top Employers Survey findings were based on approximately 5,500 completed surveys from readers of Science and other survey invitees. Respondents to the web-based survey were asked to rate companies based on 24 characteristics.

“Ionis is one of a kind, and the culture we’ve built over the last three decades is one that inspires us all to be at our best every day,” said Eric Swayze, Ph.D., executive vice president, research, Ionis. “The work we do is challenging, but we are driven by a passion to help patients who are depending on us. This imperative is what focuses us, and together, we deliver bold and groundbreaking science that translates to better medicines – and we have fun doing it. When you love what you do, going to work doesn’t feel like work.”

The complete Science magazine feature and rankings can be found here. To learn more about Ionis, including career opportunities, visit Ionis.com/careers.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has marketed medicines and a leading pipeline in neurology, cardiometabolic and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Investor Contact:
D. Wade Walke, Ph.D.
info@ionis.com
760-603-2331

Ionis Media Contact:
Hayley Soffer
media@ionis.com
760-603-4679

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Release Versions

Contacts

Ionis Investor Contact:
D. Wade Walke, Ph.D.
info@ionis.com
760-603-2331

Ionis Media Contact:
Hayley Soffer
media@ionis.com
760-603-4679

More News From Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease (AxD), a rare, progressive and often fatal neurological condition. Over time, it can lead to loss of mobility and independence, along with difficulties walking, speaking, swallowing and breathing. There are currently no approved disease-modifying treatments...

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (sHTG) (TG greater than or equal to 500 mg/dL). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown pre...

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The positive opinion is now referred to the European Commission (EC) for an...
Back to Newsroom